Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Reexamination Certificate
2003-09-05
2011-10-11
Belyavskyi, Michail (Department: 1644)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
C424S577000, C435S372300
Reexamination Certificate
active
08034334
ABSTRACT:
A method of promoting the regression of a cancer in a mammal comprising: (i) administering to the mammal nonmyeloablative lymphodepleting chemotherapy, and (ii) subsequently administering: (a) autologous T-cells, which have been previously isolated, selected for highly avid recognition of an antigen of the cancer, the regression of which is to be promoted, and rapidly expanded in vitro only once, and, either concomitantly with the autologous T-cells or subsequently to the autologous T-cells, by the same route or a different route, a T-cell growth factor that promotes the growth and activation of the autologous T-cells, or (b) autologous T-cells, which have been previously isolated, selected for highly avid recognition of an antigen of the cancer, the regression of which is to be promoted, modified to express a T-cell growth factor that promotes the growth and activation of the autologous T-cells, and rapidly expanded in vitro only once, whereupon the regression of the cancer in the mammal is promoted.
REFERENCES:
patent: 4690915 (1987-09-01), Rosenberg
patent: 5126132 (1992-06-01), Rosenberg
patent: 5192537 (1993-03-01), Osband
patent: 5725855 (1998-03-01), Ochoa et al.
patent: 6447767 (2002-09-01), Slavin et al.
patent: WO 97/05239 (1997-02-01), None
patent: WO 99/24045 (1999-05-01), None
patent: WO 03/004625 (2003-01-01), None
Riddell et al J Immunol. Method, 1990, 128, pp. 189-201.
Kawakami et al PNAS, 1994, V.91, pp. 6458-6462.
Stevens et al., J. of Immunology, 1995, 154, pp. 762-771.
Berenson et al.,J. Immunol., 115(1), 234-238 (1975).
Boehm et al.,Annu. Rev. Immunol., 15, 749-795 (1997).
Dudley et al.,J. Immunother., 24(4), 363-373 (2001).
Dudley et al.,J. Immunother., 25(3), 243-251 (2002).
Eberlein et al.,J. Exp. Med., 156(2), 385-397 (1982).
Luznik et al.,Blood, 98(12), 3456-3464 (2001).
North,J. Exp. Med., 55, 1063-1074 (1982).
O'Reilly et al.,Important Adv. Oncol., 149-166 (1996).
Robbins et al.,J. Immunol., 169, 6036-6047 (2002).
Rosenberg et al.,Ann. Surg., 228(3), 307-319 (1998).
Rosenberg et al.,J. Nat'l Cancer Inst., 86(15), 1159-1166 (1994).
Rosenberg et al.,Nat. Med., 4(3), 321-327 (1998).
Rosenberg et al.,Science, 233, 1318-1321 (1986).
Seiter et al.,J. Immunother., 25(3), 252-263, (2002).
Yee et al.,J. Exp. Med., 192(11), 1637-1643 (2000).
EP Patent Application No. 03794636.5 Supplementary European Search Report dated Jan. 24, 2011.
Dudley,Journal of Immunotherapy, 22(4), 288-298 (Jul. 1, 1999).
Dudley,Science, American Association for the Advancement of Science, 298(5594), 805-854 (Oct. 25, 2002).
Overwijk et al.,The Cancer Journal from Scientific American(Online), Feb. 1-7, 2008, retrieved from the internet: URL:http://www.ncbi,nlm.nih.gov/pmc/articles/PMC2538796/pdf
ihms65816.pdf.
Rosenberg et al.,Journal of the National Cancer Institute, 86(15), 1159-1166 (Aug. 3, 1994).
Dudley Mark E
Rosenberg Steven A
Wunderlich John R
Belyavskyi Michail
Leydig & Voit & Mayer
The United States of America as represented by the Secretary, De
LandOfFree
Immunotherapy with in vitro-selected antigen-specific... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunotherapy with in vitro-selected antigen-specific..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunotherapy with in vitro-selected antigen-specific... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4271300